These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 16116250)

  • 21. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
    Johansson BE; Kilbourne ED
    Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A one-size-fits-all flu vaccine?
    Kaiser J
    Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
    [No Abstract]   [Full Text] [Related]  

  • 24. Trends in development of the influenza vaccine with broader cross-protection.
    Stropkovská A; Janulíková J; Varecková E
    Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice.
    Webster RG; Askonas BA
    Eur J Immunol; 1980 May; 10(5):396-401. PubMed ID: 6967815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
    Lo CY; Wu Z; Misplon JA; Price GE; Pappas C; Kong WP; Tumpey TM; Epstein SL
    Vaccine; 2008 Apr; 26(17):2062-72. PubMed ID: 18378366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against lethal influenza virus encephalitis by intranasally primed CD8+ memory T cells.
    Stevenson PG; Hawke S; Bangham CR
    J Immunol; 1996 Oct; 157(7):3065-73. PubMed ID: 8816416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and use of fowlpox vectored vaccines for avian influenza.
    Bublot M; Pritchard N; Swayne DE; Selleck P; Karaca K; Suarez DL; Audonnet JC; Mickle TR
    Ann N Y Acad Sci; 2006 Oct; 1081():193-201. PubMed ID: 17135511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype.
    Govorkova EA; Smirnov YuA
    Acta Virol; 1997 Oct; 41(5):251-7. PubMed ID: 9607078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic relationships, serological cross-reaction and cross-protection between H1N2 and other influenza A virus subtypes endemic in European pigs.
    Reeth KV; Brown I; Essen S; Pensaert M
    Virus Res; 2004 Jul; 103(1-2):115-24. PubMed ID: 15163499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE; Soboleski MR; Lo CY; Misplon JA; Pappas C; Houser KV; Tumpey TM; Epstein SL
    Vaccine; 2009 Nov; 27(47):6512-21. PubMed ID: 19729082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
    Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
    Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.